KYMR— Kymera Therapeutics, Inc.

Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy

A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration Progress

FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic Asthma

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug

Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma

Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance Risks